Immunohistochemical demonstration of MET overexpression in human intrahepatic cholangiocarcinoma and in hepatolithiasis.
about
Hepatolithiasis and intrahepatic cholangiocarcinoma: A review.An Omics Perspective on Molecular Biomarkers for Diagnosis, Prognosis, and Therapeutics of CholangiocarcinomaThe significance of genetics for cholangiocarcinoma developmentIntrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapiesImmunohistochemical expression of receptor tyrosine kinase PDGFR-α, c-Met, and EGFR in skull base chordoma.Involvement of PI3K and ERK1/2 pathways in hepatocyte growth factor-induced cholangiocarcinoma cell invasion.Expression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines.Risk factors for gallbladder cancer and cholangiocarcinoma: similarities, differences and updates.Biliary cancer growth factor pathways, cyclo-oxygenase-2 and potential therapeutic strategies.Intra-hepatic and extra-hepatic cholangiocarcinoma: New insight into epidemiology and risk factors.Dramatic response to dabrafenib and trametinib combination in a BRAF V600E-mutated cholangiocarcinoma: implementation of a molecular tumour board and next-generation sequencing for personalized medicine.Cholangiocarcinoma: recent progress. Part 2: molecular pathology and treatment.Establishment and characterization of an opisthorchiasis-associated cholangiocarcinoma cell line (KKU-100).Characterization of a novel rat cholangiocarcinoma cell culture model-CGCCAPrognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinomaExpression of c-MET in Invasive MeningiomaPatterns of chromosomal copy-number alterations in intrahepatic cholangiocarcinomaThe tyrosine kinase c-Met contributes to the pro-tumorigenic function of the p38 kinase in human bile duct cholangiocarcinoma cellsMolecular genetics and targeted therapeutics in biliary tract carcinoma.Value of c-Met for Predicting Progression of Precancerous Gastric Lesions in Rural Chinese Population.Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment.Cholangiocarcinoma: Biology, Clinical Management, and Pharmacological Perspectives.Cyclooxygenase-2 is involved in the up-regulation of matrix metalloproteinase-9 in cholangiocarcinoma induced by tumor necrosis factor-alpha.c-Met targeted therapy of cholangiocarcinomaRisk factors for intrahepatic cholangiocarcinoma: a case-control study in China.Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinomaLiver stem cells and hepatocellular carcinoma.A perspective on molecular therapy in cholangiocarcinoma: present status and future directions.Targeted therapy for biliary tract cancers.Biliary tract carcinoma: clinical perspectives on molecular targeting strategies for therapeutic options.Molecular aspects of cholangiocarcinoma.New Horizons for Precision Medicine in Biliary Tract Cancers.Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).Bile acid accelerates erbB2-induced pro-tumorigenic activities in biliary tract cancer.Intrahepatic cholangiocarcinoma: current management and emerging therapies.Emerging molecular therapeutic targets for cholangiocarcinoma.Expression of glial cell line-derived neurotrophic factor correlates with perineural invasion of bile duct carcinoma.Urinary bladder urothelial carcinoma with expression of KIT and PDGFRA and showing diverse differentiations into plasmacytoid, clear cell, acantholytic, nested, and spindle variants, and into adenocarcinoma, signet-ring cell carcinoma, small cell caThe Clinical Impact of c-MET Over-Expression in Advanced Biliary Tract Cancer (BTC).
P2860
Q26771199-EE4C1AC9-8A9A-49D9-AD25-C665AEB2F3DDQ26784091-AEF2BA57-4865-46B2-9A78-A321440B0AC5Q26865749-AA34EA54-8A89-41CF-9EAC-5AF0D9397BFCQ27002547-7ECC3A23-E29F-49EE-830E-2C4DB7CC1859Q33275402-F4E86758-44C5-4565-9E64-7573D5F8D0DFQ33529782-2D6EF413-1258-4B32-A738-E9BFC9E50DE9Q33611056-9CAB7612-F586-48B3-9CC7-62F783DC9586Q34186338-F9E87B9A-8D3F-41AD-8B20-197EC69D7720Q34253944-996A17AB-09AB-478C-A9FD-AB30AA19D267Q34398255-39E218DD-45D8-4E56-B8CB-4BB9F9A605ADQ34550326-9DEF3B77-8CC3-4BCC-97E5-7334FBB266F4Q34803024-12C91E49-FD7D-43DE-8391-FB5CA8C70901Q35045355-28B8E676-EB8F-43A5-BBBF-FCC8DFF27908Q35085981-1F379506-4ABE-4629-903D-195262C00367Q35108386-20884372-9918-41E9-95A9-09FF1863D681Q35170717-3BE25DB4-C68E-4FC7-8AE2-209954D20749Q35215602-C59F55C8-B662-47DA-AB94-422CB259B442Q36407783-F9812295-03C5-4F89-ADEB-B2C906A8D089Q36488070-ED28A076-BB04-41C6-A64E-1DDAD39FDE27Q36563092-B59F5C92-8125-49B1-9F7F-0044C00314C6Q36759538-C6197151-10B2-42DF-8478-BDF891B23297Q36900063-1EA2E216-B238-4B4C-8E84-1644BAD636AAQ36962011-5870BCFB-54DF-473D-9191-0D1B6A24F783Q37150765-0404ED09-7FF2-40D7-8B54-AC8CDD178AEBQ37169357-BB817EBE-6880-4D67-8568-AB28775C4E69Q37189634-5EA1E7C6-8EB5-4A8C-8B55-11605FD9D9D4Q37351498-0EBCCDD9-D1F0-43F0-BE42-810285211430Q37358938-95A9CB75-18A0-4C8C-A9B3-FE23A2856BB8Q37719383-A3A454F3-4592-43AB-BDDA-345D603CE2D1Q37982650-3570CFB2-319F-4121-AE07-D0331C18835CQ38017118-425513D7-3B6F-41FB-AE8B-310FD1EC7D08Q38178190-CAB6E98B-589A-4C66-B11C-3AEEC1B4A159Q38619219-CB0E9D03-BD29-4A1A-AD95-32DD48197721Q38812588-DAA81A26-9ECC-4BC4-ACE8-08A215226E75Q38993903-67CB8F60-69B2-4BE3-8611-6746BB79BC6BQ39186928-3A23D24B-F679-4AEC-ACEA-8FBD39A69C1CQ39227356-359269A8-A495-4BEA-B7CF-499740F5AE58Q40754057-47E9AE32-5275-47D6-88E7-09F146E83126Q40809712-3074E0FD-16F1-4609-B735-4705B5EEA372Q41077332-33EA8421-9CF3-4525-A739-22DBBE441EA1
P2860
Immunohistochemical demonstration of MET overexpression in human intrahepatic cholangiocarcinoma and in hepatolithiasis.
description
1998 nî lūn-bûn
@nan
1998 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Immunohistochemical demonstrat ...... cinoma and in hepatolithiasis.
@ast
Immunohistochemical demonstrat ...... cinoma and in hepatolithiasis.
@en
Immunohistochemical demonstrat ...... cinoma and in hepatolithiasis.
@nl
type
label
Immunohistochemical demonstrat ...... cinoma and in hepatolithiasis.
@ast
Immunohistochemical demonstrat ...... cinoma and in hepatolithiasis.
@en
Immunohistochemical demonstrat ...... cinoma and in hepatolithiasis.
@nl
prefLabel
Immunohistochemical demonstrat ...... cinoma and in hepatolithiasis.
@ast
Immunohistochemical demonstrat ...... cinoma and in hepatolithiasis.
@en
Immunohistochemical demonstrat ...... cinoma and in hepatolithiasis.
@nl
P2093
P921
P1433
P1476
Immunohistochemical demonstrat ...... cinoma and in hepatolithiasis.
@en
P2093
P304
P356
10.1016/S0046-8177(98)90229-5
P407
P577
1998-02-01T00:00:00Z